According to the bafoon running this he stated when he was on the call that they were in constant communication with the FDA as did the President of the company... and that unblinding it was in our best interest because they did not feel the FDA would require more data... that seems like a load of BS now...
As for funds I think they will indeed need more.. none of what they have told us about having cash on hand did not mention anything about funding another Phase III trial for OAK... so something has to give... and I doubt it will be any of the salary for the new board members or for the President, CFO and CEO so that leaves shareholders having to take the brunt of the cost in the form of dilution.
News 
Market Data 
Discover 
AI
